



18 March 2022

## ASX ANNOUNCEMENT

### AstraZeneca extends and increases Renal Contract

#### Key Highlights

- **AstraZeneca extends its second contract for a Phase IIb trial, which is utilising SOZO<sup>®</sup> to measure fluid volume in patients with chronic kidney disease, by 3 months.**
- **In addition to extending the contract, AstraZeneca has increased the number of SOZO devices required by 23, taking the total number in this trial to 223.**
- **The extension and expansion of this trial will generate an estimated value of over \$500k in additional revenue to be recognised in coming quarters.**
- **In total, over \$5.5 million in contract value has been signed under the various AstraZeneca trial agreements, with just over \$2.0 million remaining to be recognised in the coming quarters.**
- **The Company anticipates a range of 250-350 SOZO devices will remain under active contracts over the balance of the trials, as sites begin to complete their portion of testing.**

ImpediMed Limited (ASX:IPD), today announced the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease. The study has been extended from 18 months to 21 months and the number of SOZO devices increased from 200 to 223.

In total, the contracts are expected to generate over \$5.5 million in revenue across the trials. The Company recognised approximately \$3.5 million in revenue under these contracts through 31 December 2021. The remainder of the revenue will be recognised throughout the second half of FY'22 and first half of FY'23.

The Company previously announced AstraZeneca is using SOZO to track patient fluid volume in two separate clinical trials. The first is focused on heart failure and chronic kidney disease and the second only on chronic kidney disease. A combined 434 SOZO devices have been leased across over 28 countries for both trials.

The Company anticipates a range of 250-350 SOZO devices will remain under active contracts over the balance of the trials, as sites begin to complete their portion of testing.

The AstraZeneca study using SOZO will evaluate the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in patients with chronic kidney disease. This Phase II trial began in January 2021 and is now scheduled to be completed in August 2022. The trial is being run by a contract research organisation on behalf of AstraZeneca.

Under the terms of the agreement, and in alignment with the Company's SaaS business model, each device will have a monthly license fee for the duration of the study. ImpediMed will retain ownership of the devices at the conclusion of the trials. The contract does not contain any material termination provisions.

“To date, the feedback on SOZO has been very positive. The trial is providing a significant number of cardiologists and nephrologists, both in the US and globally, firsthand experience with SOZO,” commented Richard Carreon, Managing Director and CEO of ImpediMed.

“Heart failure and chronic kidney disease are two of our three strategic focus areas, and this contract addition provides continued validation of the applicability of our technology in both patient populations. The endorsement is timely, as the Company starts enrollment for its renal failure trial and progresses towards an FDA clearance in Renal through the Breakthrough Device Designation Program,” he added.

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

## **Contact Details**

### **Investor relations Contact:**

Mike Bassett, ImpediMed

T: +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

## **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

## **About SOZO Digital Health Platform**

SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.